ロード中...
Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Nephrology
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2754109/ https://ncbi.nlm.nih.gov/pubmed/19762496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2008111144 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|